Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philipp Erben

Showing results (111-120 of 127) with videos related to

Pageof 13
Sort By:
BJU International|May 8, 2024
Improving detection of carcinoma in situ in bladder cancer: urinary cytology vs the Xpert® BC MonitorMaximilian Haas, Maximilian C Kriegmair, Johannes Breyer, et al.
Scientific Reports|September 18, 2023
Xpert bladder cancer monitor to predict the need for a second TURB (MoniTURB trial)Johannes Breyer, Markus Eckstein, Danijel Sikic, et al.
Urology|June 21, 2021
Prognostic Role of FGFR Alterations and FGFR mRNA Expression in Metastatic Urothelial Cancer Undergoing Checkpoint Inhibitor TherapyKarl H Tully, Hendrik Jütte, Ralph M Wirtz, et al.
Blood|August 21, 2013
Comprehensive mutational profiling in advanced systemic mastocytosisJuliana Schwaab, Susanne Schnittger, Karl Sotlar, et al.
Journal for Immunotherapy of Cancer|May 26, 2020
Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapyMarkus Eckstein, Pamela Strissel, Reiner Strick, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2018
Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumabMarkus Eckstein, Philipp Erben, Maximilian C Kriegmair, et al.
Genes, Chromosomes & Cancer|April 11, 2012
SNP array analysis of acute promyelocytic leukemia may be of prognostic relevance and identifies a potential high risk group with recurrent deletions on chromosomal subband 1q31.3Daniel Nowak, Marion Klaumuenzer, Benjamin Hanfstein, et al.
Blood|February 15, 2007
Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemiaJelena V Jovanovic, Joannah Score, Katherine Waghorn, et al.
European Urology|November 13, 2022
Spatial Immunephenotypes of Distant Metastases but not Matched Primary Urothelial Carcinomas Predict Response to Immune Checkpoint InhibitionFranziska Erlmeier, Niklas Klümper, Laura Landgraf, et al.
Anticancer Research|March 29, 2022
Baseline Modified Glasgow Prognostic Score (mGPS) Predicts Radiologic Response and Overall Survival in Metastatic Hormone-sensitive Prostate Cancer Treated With Docetaxel ChemotherapyManuel Neuberger, Janina Skladny, Nora Goly, et al.
Pageof 13

Showing results (111-120 of 127) with videos related to

Sort By:
Pageof 13
BJU International|May 8, 2024
Improving detection of carcinoma in situ in bladder cancer: urinary cytology vs the Xpert® BC MonitorMaximilian Haas, Maximilian C Kriegmair, Johannes Breyer, et al.
Scientific Reports|September 18, 2023
Xpert bladder cancer monitor to predict the need for a second TURB (MoniTURB trial)Johannes Breyer, Markus Eckstein, Danijel Sikic, et al.
Urology|June 21, 2021
Prognostic Role of FGFR Alterations and FGFR mRNA Expression in Metastatic Urothelial Cancer Undergoing Checkpoint Inhibitor TherapyKarl H Tully, Hendrik Jütte, Ralph M Wirtz, et al.
Blood|August 21, 2013
Comprehensive mutational profiling in advanced systemic mastocytosisJuliana Schwaab, Susanne Schnittger, Karl Sotlar, et al.
Journal for Immunotherapy of Cancer|May 26, 2020
Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapyMarkus Eckstein, Pamela Strissel, Reiner Strick, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2018
Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumabMarkus Eckstein, Philipp Erben, Maximilian C Kriegmair, et al.
Genes, Chromosomes & Cancer|April 11, 2012
SNP array analysis of acute promyelocytic leukemia may be of prognostic relevance and identifies a potential high risk group with recurrent deletions on chromosomal subband 1q31.3Daniel Nowak, Marion Klaumuenzer, Benjamin Hanfstein, et al.
Blood|February 15, 2007
Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemiaJelena V Jovanovic, Joannah Score, Katherine Waghorn, et al.
European Urology|November 13, 2022
Spatial Immunephenotypes of Distant Metastases but not Matched Primary Urothelial Carcinomas Predict Response to Immune Checkpoint InhibitionFranziska Erlmeier, Niklas Klümper, Laura Landgraf, et al.
Anticancer Research|March 29, 2022
Baseline Modified Glasgow Prognostic Score (mGPS) Predicts Radiologic Response and Overall Survival in Metastatic Hormone-sensitive Prostate Cancer Treated With Docetaxel ChemotherapyManuel Neuberger, Janina Skladny, Nora Goly, et al.
Pageof 13